Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

590 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survey of high-resolution archaeal virus structures.
Hartman R, Munson-McGee J, Young MJ, Lawrence CM. Hartman R, et al. Curr Opin Virol. 2019 Jun;36:74-83. doi: 10.1016/j.coviro.2019.05.008. Epub 2019 Jun 22. Curr Opin Virol. 2019. PMID: 31238245 Review.
The Molecular Mechanism of Cellular Attachment for an Archaeal Virus.
Hartman R, Eilers BJ, Bollschweiler D, Munson-McGee JH, Engelhardt H, Young MJ, Lawrence CM. Hartman R, et al. Structure. 2019 Nov 5;27(11):1634-1646.e3. doi: 10.1016/j.str.2019.09.005. Epub 2019 Oct 3. Structure. 2019. PMID: 31587916 Free article.
Efficacy and safety of evenamide, a glutamate modulator, added to a second-generation antipsychotic in inadequately/poorly responding patients with chronic schizophrenia: Results from a randomized, double-blind, placebo-controlled, phase 3, international clinical trial.
Anand R, Turolla A, Chinellato G, Sansi F, Roy A, Hartman R. Anand R, et al. Among authors: hartman r. Neuropharmacology. 2024 Dec 19;266:110275. doi: 10.1016/j.neuropharm.2024.110275. Online ahead of print. Neuropharmacology. 2024. PMID: 39708914 Free article.
Therapeutic Effect of Evenamide, a Glutamate Inhibitor, in Patients With Treatment-Resistant Schizophrenia (TRS): Final, 1-Year Results From a Phase 2, Open-Label, Rater-Blinded, Randomized, International Clinical Trial.
Anand R, Turolla A, Chinellato G, Roy A, Hartman RD. Anand R, et al. Among authors: hartman rd. Int J Neuropsychopharmacol. 2024 Dec 28;28(1):pyae061. doi: 10.1093/ijnp/pyae061. Int J Neuropsychopharmacol. 2024. PMID: 39661380 Free PMC article. Clinical Trial.
590 results